## Contents

Со	ntributors	xi
En	docrine disrupting chemicals: Understanding what matters	xiii
1.	Endocrine disruptor global policy	1
		-
	1. Introduction	2
	2. Current approaches to regulating EDCs	4
	Conclusion     Conclusion	20
	Conflict of interest statement	. 24
	References	25
_		25
2.	loxicity testing and endocrine disrupting chemicals	35
	Laura N. Vandenberg	
	1. Introduction	36
	2. Introduction to EDC testing	42
	3. Introduction to the endocrine disruptor screening program (EDSP)	47
	4. In vitro screening tests	48
	5. In vivo screening tests	52
	6. Long-term in vivo screening tests	58
	7. Improving toxicity testing for EDCs	60
	8. Conclusion	64
	Acknowledgment	65
	Conflict of interest statement	65
	References	65
3.	Epigenetics, estrogenic endocrine-disrupting chemicals (EDCs),	
	and the brain	73
	Madeline Streifer and Andrea C. Gore	
	1. Introduction	74
	2. Hormones and sex differences in the developing brain	75
	3. Endocrine-disrupting chemicals	79
	4. Hormones and epigenetic mechanisms in the brain	82
	5. Epigenetics and EDCs	89
	6. Conclusion	92
	Conflict of interest statement	93
	References	93
		v

vi	Contents

x

4.	Endocrine disrupting chemicals (EDCs) and the neuroendocrine system: Beyond estrogen, androgen, and thyroid Heather B. Patisaul	1 <b>01</b>
	1. Introduction	103
	2. The EDC landscape	105
	3. The emergence of the neuroendocrine disruption concept	108
	4. The neuroendocrine system	110
	5. Development and sexual differentiation of the neuroendocrine system	114
	6. Neuroendocrine disruption of the structure and function of the HPG axis	116
	7. Neuroendocrine disruption and metabolic programming	122
	8. Beyond EA&T: Emerging areas of neuroendocrine disruption	127
	9. Conclusion	129
	Acknowledgments	131
	Conflict of interest statement	131
	References	131
5.	Endocrine disrupting chemicals and reproductive disorders in women, men, and animal models	151
	Mary Jo Laws, Alison M. Neff, Emily Brehm, Genoa R. Warner, and	
	Jodi A. Flaws	
	1. Introduction	152
	2. Female reproductive disorders	154
	3. Male reproductive disorders	165
	4. Conclusion	171
	Acknowledgments	171
	Conflict of interest statement	171
	References	171
6.	Endocrine disrupting chemicals (EDCs) and sex steroid receptors	191
	Julianne M. Hall and Kenneth S. Korach	
	1. Introduction	193
	2. The sex steroid receptors (ERs, PRs, AR) as cellular targets for EDC action	193
	3. Sex steroid receptor general MOA	194
	4. EDCs that interact with SSRs	197
	5. Molecular mechanisms of EDC action on sex steroid receptors	200
	6. Pathological consequences of EDC action on sex steroid receptors	208
	7. Conclusions	219
	Acknowledgments	219
	Conflict of interest	219
	References	220

Contents		
7.	Endocrine disrupting chemicals and the mammary aland	237
	Laura N. Vandenberg	
	1. Introduction	238
	2. Overview of mammary gland biology	240
	3. Lactation is important to the baby and the mother	247
	4. The role of hormones in mammary gland development	248
	5. Developmental origins of adult diseases	253
	6. EDCs and mammary gland development	256
	7. EDCs and sensitization of the mammary gland	260
	8. EDCs and lactation	261
	9. EDCs and gynecomastia	263
	10. Conclusions	265
	Acknowledgments	266
	Conflict of interest statement	266
	References	266
	Impact of gestational exposure to endocrine disrupting	
	chemicals on pregnancy and birth outcomes	279
	Vasantha Padmanabhan, Jacob Moeller, and Muraly Puttabyatappa	
	1. Introduction	281
	2. Endocrine disrupting chemicals (EDCs)	281
	3. Mechanisms of EDC action during pregnancy	299
	4. Modulation of EDCs effects	305
	5. Long term implications of gestational EDC exposure	307
	6. Limitations of available human data	317
	7. Conclusion	317
	Conflict of interest statement	319
	References	319
	Endowing discussing showing (FDCs) and placental functions	
	Impact on fetal brain development	347
	William P. Marinello and Heather B. Patisaul	2.7
	1 Introduction	340
	2 Placental formation	350
	3 Placenta functions	356
	4. The placenta as a neuroendocrine organ	363
	5. Conclusion	376
	Acknowledgments	380
	Conflict of interest	380
	References	300
	Hereinees	500

Cor	iter	nts
-----	------	-----

10.	Endocrine disrupting chemicals and thyroid hormone action B. Thomas Zoeller	401
		400
	1. Introduction	402
	2. Invited normone and development	403
	Polychiorinated biphenyls (PCBs) and thyroid hormone     Polychiorinated biphenyls (PCBs) and thyroid hormone	404
	4. Perchiorate and thyroid normone	400
	5. Bisphenol A (BPA)	400
	6. Conclusion	411
	References	413
11.	Inappropriately sweet: Environmental endocrine-disrupting chemicals and the diabetes pandemic	419
	1. Introduction	420
	2. Pathogenesis of type 2 diabetes mellitus	422
	3. Endocrine-disrupting chemicals (EDCs)	424
	4. EDCs and pathways to environmentally-mediated diabetes	426
	5. EDCs and type 1 diabetes	438
	6. EDCs and gestational diabetes	439
	7. EDCs, diabetes disparities, and health justice	440
	<ol> <li>Crosstalk between clinical care and EDC exposure</li> <li>Bridging the gap to address accurately of diskates risk.</li> </ol>	440
	9. Bridging the gap to address ecosystems of diabetes risk	441
	11. Conclusion	442
	Acknowledgements	۲ <del>۰۰</del> ۸۸۸
	Conflict of interest statement	444
	References	444
12.	The new kids on the block: Emerging obesogens Raquel Chamorro-Garcia and Almudena Veiga-Lopez	457
	1 Introduction	458
	2 Adipose tissue: An overview	459
	3. Obesogens, environmental factors that interfere with adipose tissue	100
	metabolism	462
	4. Emerging obesogens: The new kids on the block	464
	5. Approaches and reproducibility	472
	6. Conclusions and future directions	473
	Acknowledgments	475
	Conflict of interest	475
	References	475

Contents		ix
13.	Endocrine disrupting chemicals and breast cancer cells	485
		100
	Introduction     Specific entry for breast concer	480
	2. EDCs as fisk factors for breast cancer	487
	<ol> <li>Epidemiological studies of EDCs and bleast cancel</li> <li>EDCs and the belimptic of cancer</li> </ol>	490
	EDCS and the hammarks of cancer      The tumor microopwirenment	497 507
	6. The importance of considering long-term exposures	508
	<ol> <li>The importance of considering long-term EDC actions</li> </ol>	500
	8 Conclusion	509
	Conflict of interest	510
	References	510
4.	EDCs and male urogenital cancers	521
	M.S. Bornman and N.H. Aneck-Hahn	
	1. Introduction	523
	2. Conclusion	543
	Conflict of interest statement	543
	References	543